A rare break in the action in DrugPricingLand means this is a good morning for reflection and deep work
And the net-price nuggets from yesterday's Senate hearing that went (almost) unnoticed
And a couple of IRA-lawsuit nuggets worth tracking on
Plus a study that shows looks at availability and pricing at cash-pay pharmacies
And why the IRA's first round of price controls won't tell us much about CMS thinking
And a must-read Health Affairs piece on how to improve value assessment
And a Novo exec makes clear that obesity-med prices are going down
And CMS will pilot a new way for Medicaid to pay for gene therapy
And a must-read piece about why the cost-effectiveness analyses of the future will show drugs are a great deal
And other reasons why the next 10 days in DrugPricingLand are going to be so intense
Plus: am I naive for being amazed that Optum is making loans to health care providers?
And I'm still stuck on the Arnold Ventures net-price denialism
